Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum

Background. Molluscum contagiosum (MC) is a common viral skin infection primarily affecting children which is difficult to treat using available therapeutic approaches. The sulfated polysaccharide named calcium spirulan (Ca-SP) has demonstrated antiviral effects against herpes simplex virus in kerat...

Full description

Bibliographic Details
Main Authors: Karoline Jungclaus, Rosa Mascarenhas, Oscar Tellechea, Jeremias L. K. Reich, Kristian Reich
Format: Article
Language:English
Published: Hindawi Limited 2023-01-01
Series:Dermatology Research and Practice
Online Access:http://dx.doi.org/10.1155/2023/8871299
_version_ 1797746019471982592
author Karoline Jungclaus
Rosa Mascarenhas
Oscar Tellechea
Jeremias L. K. Reich
Kristian Reich
author_facet Karoline Jungclaus
Rosa Mascarenhas
Oscar Tellechea
Jeremias L. K. Reich
Kristian Reich
author_sort Karoline Jungclaus
collection DOAJ
description Background. Molluscum contagiosum (MC) is a common viral skin infection primarily affecting children which is difficult to treat using available therapeutic approaches. The sulfated polysaccharide named calcium spirulan (Ca-SP) has demonstrated antiviral effects against herpes simplex virus in keratinocytes in vitro, and a cream containing 1.5% Ca-SP and 1% of a defined microalgae extract (Spiralin®) effectively prevented herpes labialis in a trial with susceptible individuals. This observational study aimed to show antiviral effects of a similar formulation (Spirularin® VS) against MC in children. Methods. Children with active MC lesions were treated with Spirularin® VS cream twice daily on affected skin over several months and asked to return for follow-up visits after 1 to 3 months. Clinical status of MC infection was documented at baseline and follow-up visits. Results. Of the 31 children enrolled in the study, 26 completed treatment and returned for control visits. Spirularin® VS cream was applied twice daily over a period of 1 to 9 months (mean treatment duration 3.9 months). 19/26 (73.1%) children achieved complete clearance of MC lesions with no clinical evidence of bacterial skin infection during treatment. No irritative skin reactions or unpleasant symptoms were observed or reported. Conclusion. This open-label observational study suggests that a cream formulation containing 1.5% Ca-SP and 1% Spiralin® may be an effective and safe treatment option for children with active MC lesions. The high rate of complete clearance of MC lesions and lack of adverse reactions warrant further investigation in larger, controlled trials.
first_indexed 2024-03-12T15:32:08Z
format Article
id doaj.art-11101540a19c439989ca2bc6099bffdf
institution Directory Open Access Journal
issn 1687-6113
language English
last_indexed 2024-03-12T15:32:08Z
publishDate 2023-01-01
publisher Hindawi Limited
record_format Article
series Dermatology Research and Practice
spelling doaj.art-11101540a19c439989ca2bc6099bffdf2023-08-10T00:00:01ZengHindawi LimitedDermatology Research and Practice1687-61132023-01-01202310.1155/2023/8871299Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum ContagiosumKaroline Jungclaus0Rosa Mascarenhas1Oscar Tellechea2Jeremias L. K. Reich3Kristian Reich4Center for Translational Research in Inflammatory Skin DiseasesHospital Distrital da Figueira da FozHospital Distrital da Figueira da FozOxford University Clinical Academic Graduate SchoolCenter for Translational Research in Inflammatory Skin DiseasesBackground. Molluscum contagiosum (MC) is a common viral skin infection primarily affecting children which is difficult to treat using available therapeutic approaches. The sulfated polysaccharide named calcium spirulan (Ca-SP) has demonstrated antiviral effects against herpes simplex virus in keratinocytes in vitro, and a cream containing 1.5% Ca-SP and 1% of a defined microalgae extract (Spiralin®) effectively prevented herpes labialis in a trial with susceptible individuals. This observational study aimed to show antiviral effects of a similar formulation (Spirularin® VS) against MC in children. Methods. Children with active MC lesions were treated with Spirularin® VS cream twice daily on affected skin over several months and asked to return for follow-up visits after 1 to 3 months. Clinical status of MC infection was documented at baseline and follow-up visits. Results. Of the 31 children enrolled in the study, 26 completed treatment and returned for control visits. Spirularin® VS cream was applied twice daily over a period of 1 to 9 months (mean treatment duration 3.9 months). 19/26 (73.1%) children achieved complete clearance of MC lesions with no clinical evidence of bacterial skin infection during treatment. No irritative skin reactions or unpleasant symptoms were observed or reported. Conclusion. This open-label observational study suggests that a cream formulation containing 1.5% Ca-SP and 1% Spiralin® may be an effective and safe treatment option for children with active MC lesions. The high rate of complete clearance of MC lesions and lack of adverse reactions warrant further investigation in larger, controlled trials.http://dx.doi.org/10.1155/2023/8871299
spellingShingle Karoline Jungclaus
Rosa Mascarenhas
Oscar Tellechea
Jeremias L. K. Reich
Kristian Reich
Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
Dermatology Research and Practice
title Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
title_full Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
title_fullStr Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
title_full_unstemmed Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
title_short Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
title_sort open label observational study of a topical formulation of calcium spirulan contained in a defined extract of the microalga spirulina platensis in the treatment of children with molluscum contagiosum
url http://dx.doi.org/10.1155/2023/8871299
work_keys_str_mv AT karolinejungclaus openlabelobservationalstudyofatopicalformulationofcalciumspirulancontainedinadefinedextractofthemicroalgaspirulinaplatensisinthetreatmentofchildrenwithmolluscumcontagiosum
AT rosamascarenhas openlabelobservationalstudyofatopicalformulationofcalciumspirulancontainedinadefinedextractofthemicroalgaspirulinaplatensisinthetreatmentofchildrenwithmolluscumcontagiosum
AT oscartellechea openlabelobservationalstudyofatopicalformulationofcalciumspirulancontainedinadefinedextractofthemicroalgaspirulinaplatensisinthetreatmentofchildrenwithmolluscumcontagiosum
AT jeremiaslkreich openlabelobservationalstudyofatopicalformulationofcalciumspirulancontainedinadefinedextractofthemicroalgaspirulinaplatensisinthetreatmentofchildrenwithmolluscumcontagiosum
AT kristianreich openlabelobservationalstudyofatopicalformulationofcalciumspirulancontainedinadefinedextractofthemicroalgaspirulinaplatensisinthetreatmentofchildrenwithmolluscumcontagiosum